JP2012501327A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012501327A5 JP2012501327A5 JP2011524992A JP2011524992A JP2012501327A5 JP 2012501327 A5 JP2012501327 A5 JP 2012501327A5 JP 2011524992 A JP2011524992 A JP 2011524992A JP 2011524992 A JP2011524992 A JP 2011524992A JP 2012501327 A5 JP2012501327 A5 JP 2012501327A5
- Authority
- JP
- Japan
- Prior art keywords
- solvate
- hydrate
- compound
- salt
- acetic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 198
- 150000003839 salts Chemical class 0.000 claims description 130
- 239000012453 solvate Substances 0.000 claims description 129
- -1 chloro, cyano, ethoxy Chemical group 0.000 claims description 43
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 35
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 34
- 229910052799 carbon Inorganic materials 0.000 claims description 32
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 28
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 26
- 208000035475 disorder Diseases 0.000 claims description 24
- 229910052736 halogen Inorganic materials 0.000 claims description 22
- 150000002367 halogens Chemical class 0.000 claims description 22
- 150000004677 hydrates Chemical class 0.000 claims description 21
- 102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 claims description 20
- 108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims description 14
- 238000004519 manufacturing process Methods 0.000 claims description 14
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims description 14
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 14
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 12
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 12
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 10
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 10
- 208000011231 Crohn disease Diseases 0.000 claims description 10
- 201000004681 Psoriasis Diseases 0.000 claims description 10
- 206010052779 Transplant rejections Diseases 0.000 claims description 10
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 10
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 10
- 206010000496 acne Diseases 0.000 claims description 10
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 10
- 125000001153 fluoro group Chemical group F* 0.000 claims description 10
- 125000001072 heteroaryl group Chemical group 0.000 claims description 10
- 208000027866 inflammatory disease Diseases 0.000 claims description 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 10
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 10
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 10
- 201000006417 multiple sclerosis Diseases 0.000 claims description 9
- 208000023275 Autoimmune disease Diseases 0.000 claims description 6
- 150000003857 carboxamides Chemical class 0.000 claims description 6
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 6
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 6
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 6
- 125000000623 heterocyclic group Chemical group 0.000 claims description 6
- 125000002346 iodo group Chemical group I* 0.000 claims description 6
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 6
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 claims description 6
- 206010055171 Hypertensive nephropathy Diseases 0.000 claims description 5
- 206010063837 Reperfusion injury Diseases 0.000 claims description 5
- 230000001580 bacterial effect Effects 0.000 claims description 5
- 206010061989 glomerulosclerosis Diseases 0.000 claims description 5
- 210000004698 lymphocyte Anatomy 0.000 claims description 5
- 230000001404 mediated effect Effects 0.000 claims description 5
- 208000031225 myocardial ischemia Diseases 0.000 claims description 5
- CKDWPUIZGOQOOM-UHFFFAOYSA-N Carbamyl chloride Chemical compound NC(Cl)=O CKDWPUIZGOQOOM-UHFFFAOYSA-N 0.000 claims description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 4
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 4
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 4
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 2
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims description 2
- OURDNEYNJXXFAW-UHFFFAOYSA-N 2-[2-[(3,4-diethoxyphenyl)methoxy]-6,7,8,9-tetrahydropyrido[1,2-a]indol-9-yl]acetic acid Chemical compound C1=C(OCC)C(OCC)=CC=C1COC1=CC=C(N2C(C(CC(O)=O)CCC2)=C2)C2=C1 OURDNEYNJXXFAW-UHFFFAOYSA-N 0.000 claims description 2
- ZSCIYHDDJFZICO-UHFFFAOYSA-N 2-[2-[(3-cyano-4-propan-2-yloxyphenyl)methoxy]-6,7,8,9-tetrahydropyrido[1,2-a]indol-9-yl]acetic acid Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1COC1=CC=C(N2C(C(CC(O)=O)CCC2)=C2)C2=C1 ZSCIYHDDJFZICO-UHFFFAOYSA-N 0.000 claims description 2
- XQMAHKURCKRHEI-UHFFFAOYSA-N 2-[2-[[3,5-bis(trifluoromethyl)phenyl]methoxy]-6,7,8,9-tetrahydropyrido[1,2-a]indol-9-yl]acetic acid Chemical compound OC(=O)CC1CCCN(C2=CC=3)C1=CC2=CC=3OCC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 XQMAHKURCKRHEI-UHFFFAOYSA-N 0.000 claims description 2
- IIOPUDVNOKQNDK-UHFFFAOYSA-N 2-[2-[[3-cyano-5-(trifluoromethoxy)phenyl]methoxy]-6,7,8,9-tetrahydropyrido[1,2-a]indol-9-yl]acetic acid Chemical compound OC(=O)CC1CCCN(C2=CC=3)C1=CC2=CC=3OCC1=CC(OC(F)(F)F)=CC(C#N)=C1 IIOPUDVNOKQNDK-UHFFFAOYSA-N 0.000 claims description 2
- HXJHNTSVKACFNI-UHFFFAOYSA-N 2-[2-[[4-cyclopentyl-3-(trifluoromethyl)phenyl]methoxy]-6,7,8,9-tetrahydropyrido[1,2-a]indol-9-yl]acetic acid Chemical compound OC(=O)CC1CCCN(C2=CC=3)C1=CC2=CC=3OCC(C=C1C(F)(F)F)=CC=C1C1CCCC1 HXJHNTSVKACFNI-UHFFFAOYSA-N 0.000 claims description 2
- YYERQLHBQBHYKE-UHFFFAOYSA-N 2-[2-[[4-propan-2-yloxy-3-(trifluoromethyl)phenyl]methoxy]-6,7,8,9-tetrahydropyrido[1,2-a]indol-9-yl]acetic acid Chemical compound C1=C(C(F)(F)F)C(OC(C)C)=CC=C1COC1=CC=C(N2C(C(CC(O)=O)CCC2)=C2)C2=C1 YYERQLHBQBHYKE-UHFFFAOYSA-N 0.000 claims description 2
- VZAQJICHENMYSC-UHFFFAOYSA-N 2-[4-bromo-6-[[4-cyclopentyl-3-(trifluoromethyl)phenyl]methoxy]-2,3-dihydro-1h-pyrrolo[1,2-a]indol-3-yl]acetic acid Chemical compound OC(=O)CC1CCN(C2=CC=3)C1=C(Br)C2=CC=3OCC(C=C1C(F)(F)F)=CC=C1C1CCCC1 VZAQJICHENMYSC-UHFFFAOYSA-N 0.000 claims description 2
- RFHZEVOYOUGNKA-UHFFFAOYSA-N 2-[4-chloro-6-[(3-cyano-4-methoxyphenyl)methoxy]-2,3-dihydro-1h-pyrrolo[1,2-a]indol-3-yl]acetic acid Chemical compound C1=C(C#N)C(OC)=CC=C1COC1=CC=C(N2C(C(CC(O)=O)CC2)=C2Cl)C2=C1 RFHZEVOYOUGNKA-UHFFFAOYSA-N 0.000 claims description 2
- RWFBHHNEDFDSPE-UHFFFAOYSA-N 2-[4-chloro-6-[(3-cyano-4-propan-2-yloxyphenyl)methoxy]-2,3-dihydro-1h-pyrrolo[1,2-a]indol-3-yl]acetic acid Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1COC1=CC=C(N2C(C(CC(O)=O)CC2)=C2Cl)C2=C1 RWFBHHNEDFDSPE-UHFFFAOYSA-N 0.000 claims description 2
- HAEAMGHQKYAHSN-UHFFFAOYSA-N 2-[4-chloro-6-[(3-cyano-4-propan-2-yloxyphenyl)methoxy]-5-methyl-2,3-dihydro-1h-pyrrolo[1,2-a]indol-3-yl]acetic acid Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1COC1=CC=C(N2C(C(CC(O)=O)CC2)=C2Cl)C2=C1C HAEAMGHQKYAHSN-UHFFFAOYSA-N 0.000 claims description 2
- PDNPVIUOUJZEMZ-UHFFFAOYSA-N 2-[4-chloro-6-[[3-chloro-4-(1,3-difluoropropan-2-yloxy)phenyl]methoxy]-2,3-dihydro-1h-pyrrolo[1,2-a]indol-3-yl]acetic acid Chemical compound OC(=O)CC1CCN(C2=CC=3)C1=C(Cl)C2=CC=3OCC1=CC=C(OC(CF)CF)C(Cl)=C1 PDNPVIUOUJZEMZ-UHFFFAOYSA-N 0.000 claims description 2
- ZTJAHQOYCPJNBO-UHFFFAOYSA-N 2-[4-chloro-6-[[4-(cyclopropylmethoxy)-3-(trifluoromethyl)phenyl]methoxy]-2,3-dihydro-1h-pyrrolo[1,2-a]indol-3-yl]acetic acid Chemical compound OC(=O)CC1CCN(C2=CC=3)C1=C(Cl)C2=CC=3OCC(C=C1C(F)(F)F)=CC=C1OCC1CC1 ZTJAHQOYCPJNBO-UHFFFAOYSA-N 0.000 claims description 2
- YHDXYXKHTNGYGO-UHFFFAOYSA-N 2-[4-chloro-6-[[4-(fluoromethoxy)-3-(trifluoromethyl)phenyl]methoxy]-2,3-dihydro-1h-pyrrolo[1,2-a]indol-3-yl]acetic acid Chemical compound OC(=O)CC1CCN(C2=CC=3)C1=C(Cl)C2=CC=3OCC1=CC=C(OCF)C(C(F)(F)F)=C1 YHDXYXKHTNGYGO-UHFFFAOYSA-N 0.000 claims description 2
- KMLYXCLMDMRYDN-UHFFFAOYSA-N 2-[4-chloro-6-[[4-cyclopentyl-3-(trifluoromethyl)phenyl]methoxy]-2,3-dihydro-1h-pyrrolo[1,2-a]indol-3-yl]acetic acid Chemical compound OC(=O)CC1CCN(C2=CC=3)C1=C(Cl)C2=CC=3OCC(C=C1C(F)(F)F)=CC=C1C1CCCC1 KMLYXCLMDMRYDN-UHFFFAOYSA-N 0.000 claims description 2
- RLGFHVZCVPTTLP-UHFFFAOYSA-N 2-[4-chloro-6-[[4-propan-2-yloxy-3-(trifluoromethyl)phenyl]methoxy]-2,3-dihydro-1h-pyrrolo[1,2-a]indol-3-yl]acetic acid Chemical compound C1=C(C(F)(F)F)C(OC(C)C)=CC=C1COC1=CC=C(N2C(C(CC(O)=O)CC2)=C2Cl)C2=C1 RLGFHVZCVPTTLP-UHFFFAOYSA-N 0.000 claims description 2
- HUWYAKMXVLYYCB-UHFFFAOYSA-N 2-[4-cyclobutyl-6-[[4-cyclopentyl-3-(trifluoromethyl)phenyl]methoxy]-2,3-dihydro-1h-pyrrolo[1,2-a]indol-3-yl]acetic acid Chemical compound OC(=O)CC1CCN(C2=CC=C(OCC=3C=C(C(C4CCCC4)=CC=3)C(F)(F)F)C=C22)C1=C2C1CCC1 HUWYAKMXVLYYCB-UHFFFAOYSA-N 0.000 claims description 2
- QBXWFAZAVUOKML-UHFFFAOYSA-N 2-[4-methyl-6-[[4-propan-2-yloxy-3-(trifluoromethyl)phenyl]methoxy]-2,3-dihydro-1h-pyrrolo[1,2-a]indol-3-yl]acetic acid Chemical compound C1=C(C(F)(F)F)C(OC(C)C)=CC=C1COC1=CC=C(N2C(C(CC(O)=O)CC2)=C2C)C2=C1 QBXWFAZAVUOKML-UHFFFAOYSA-N 0.000 claims description 2
- YSVIGFUSBHVXQF-UHFFFAOYSA-N 2-[6-[(3,4-diethoxyphenyl)methoxy]-2,3-dihydro-1h-pyrrolo[1,2-a]indol-3-yl]acetic acid Chemical compound C1=C(OCC)C(OCC)=CC=C1COC1=CC=C(N2C(C(CC(O)=O)CC2)=C2)C2=C1 YSVIGFUSBHVXQF-UHFFFAOYSA-N 0.000 claims description 2
- YROGAKZEXADMCC-UHFFFAOYSA-N 2-[6-[(3-cyano-4-cyclohexylphenyl)methoxy]-2,3-dihydro-1h-pyrrolo[1,2-a]indol-3-yl]acetic acid Chemical compound OC(=O)CC1CCN(C2=CC=3)C1=CC2=CC=3OCC(C=C1C#N)=CC=C1C1CCCCC1 YROGAKZEXADMCC-UHFFFAOYSA-N 0.000 claims description 2
- RXTPJDXUECAAGM-UHFFFAOYSA-N 2-[6-[(3-cyano-4-cyclopentylphenyl)methoxy]-2,3-dihydro-1h-pyrrolo[1,2-a]indol-3-yl]acetic acid Chemical compound OC(=O)CC1CCN(C2=CC=3)C1=CC2=CC=3OCC(C=C1C#N)=CC=C1C1CCCC1 RXTPJDXUECAAGM-UHFFFAOYSA-N 0.000 claims description 2
- CQJMGIUYXGQKNP-UHFFFAOYSA-N 2-[6-[(3-cyano-4-methoxyphenyl)methoxy]-2,3-dihydro-1h-pyrrolo[1,2-a]indol-3-yl]acetic acid Chemical compound C1=C(C#N)C(OC)=CC=C1COC1=CC=C(N2C(C(CC(O)=O)CC2)=C2)C2=C1 CQJMGIUYXGQKNP-UHFFFAOYSA-N 0.000 claims description 2
- PLHKTXYJCYEKDM-UHFFFAOYSA-N 2-[6-[(3-cyano-4-propan-2-yloxyphenyl)methoxy]-2,3-dihydro-1h-pyrrolo[1,2-a]indol-3-yl]acetic acid Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1COC1=CC=C(N2C(C(CC(O)=O)CC2)=C2)C2=C1 PLHKTXYJCYEKDM-UHFFFAOYSA-N 0.000 claims description 2
- XVAKSXTWMLJFSC-UHFFFAOYSA-N 2-[6-[(3-cyano-4-propan-2-yloxyphenyl)methoxy]-4-methyl-2,3-dihydro-1h-pyrrolo[1,2-a]indol-3-yl]acetic acid Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1COC1=CC=C(N2C(C(CC(O)=O)CC2)=C2C)C2=C1 XVAKSXTWMLJFSC-UHFFFAOYSA-N 0.000 claims description 2
- NPNHJHMGCDPLBF-UHFFFAOYSA-N 2-[6-[(3-cyano-4-propan-2-yloxyphenyl)methoxy]-4-methylsulfonyl-2,3-dihydro-1h-pyrrolo[1,2-a]indol-3-yl]acetic acid Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1COC1=CC=C(N2C(C(CC(O)=O)CC2)=C2S(C)(=O)=O)C2=C1 NPNHJHMGCDPLBF-UHFFFAOYSA-N 0.000 claims description 2
- QQYBDDBYWMNMBW-UHFFFAOYSA-N 2-[6-[(3-cyano-4-propan-2-yloxyphenyl)methoxy]-5-methyl-2,3-dihydro-1h-pyrrolo[1,2-a]indol-3-yl]acetic acid Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1COC1=CC=C(N2C(C(CC(O)=O)CC2)=C2)C2=C1C QQYBDDBYWMNMBW-UHFFFAOYSA-N 0.000 claims description 2
- DSAKGSUGOFICNT-UHFFFAOYSA-N 2-[6-[(4-methylsulfonylphenyl)methoxy]-2,3-dihydro-1h-pyrrolo[1,2-a]indol-3-yl]acetic acid Chemical compound C1=CC(S(=O)(=O)C)=CC=C1COC1=CC=C(N2C(C(CC(O)=O)CC2)=C2)C2=C1 DSAKGSUGOFICNT-UHFFFAOYSA-N 0.000 claims description 2
- JDLBWMCWMKVHBJ-UHFFFAOYSA-N 2-[6-[(4-pyrazol-1-ylphenyl)methoxy]-2,3-dihydro-1h-pyrrolo[1,2-a]indol-3-yl]acetic acid Chemical compound OC(=O)CC1CCN(C2=CC=3)C1=CC2=CC=3OCC(C=C1)=CC=C1N1C=CC=N1 JDLBWMCWMKVHBJ-UHFFFAOYSA-N 0.000 claims description 2
- QFVBNEUFDXTLNT-UHFFFAOYSA-N 2-[6-[[2,4-bis(trifluoromethyl)phenyl]methoxy]-2,3-dihydro-1h-pyrrolo[1,2-a]indol-3-yl]acetic acid Chemical compound OC(=O)CC1CCN(C2=CC=3)C1=CC2=CC=3OCC1=CC=C(C(F)(F)F)C=C1C(F)(F)F QFVBNEUFDXTLNT-UHFFFAOYSA-N 0.000 claims description 2
- GJNMLDLOMNJTDO-UHFFFAOYSA-N 2-[6-[[3-chloro-4-(1,3-difluoropropan-2-yloxy)phenyl]methoxy]-2,3-dihydro-1h-pyrrolo[1,2-a]indol-3-yl]acetic acid Chemical compound OC(=O)CC1CCN(C2=CC=3)C1=CC2=CC=3OCC1=CC=C(OC(CF)CF)C(Cl)=C1 GJNMLDLOMNJTDO-UHFFFAOYSA-N 0.000 claims description 2
- PFPJPOLAMPIPGS-UHFFFAOYSA-N 2-[6-[[3-cyano-5-(trifluoromethoxy)phenyl]methoxy]-2,3-dihydro-1h-pyrrolo[1,2-a]indol-3-yl]acetic acid Chemical compound OC(=O)CC1CCN(C2=CC=3)C1=CC2=CC=3OCC1=CC(OC(F)(F)F)=CC(C#N)=C1 PFPJPOLAMPIPGS-UHFFFAOYSA-N 0.000 claims description 2
- FEZLNHIXVFQJPD-UHFFFAOYSA-N 2-[6-[[4-(2-methylpropyl)-3-(trifluoromethyl)phenyl]methoxy]-2,3-dihydro-1h-pyrrolo[1,2-a]indol-3-yl]acetic acid Chemical compound C1=C(C(F)(F)F)C(CC(C)C)=CC=C1COC1=CC=C(N2C(C(CC(O)=O)CC2)=C2)C2=C1 FEZLNHIXVFQJPD-UHFFFAOYSA-N 0.000 claims description 2
- RDLRGCFRXOFKAZ-UHFFFAOYSA-N 2-[6-[[4-(cyclohexylmethyl)-3-(trifluoromethyl)phenyl]methoxy]-2,3-dihydro-1h-pyrrolo[1,2-a]indol-3-yl]acetic acid Chemical compound OC(=O)CC1CCN(C2=CC=3)C1=CC2=CC=3OCC(C=C1C(F)(F)F)=CC=C1CC1CCCCC1 RDLRGCFRXOFKAZ-UHFFFAOYSA-N 0.000 claims description 2
- JJIPBGSMNCDBMS-UHFFFAOYSA-N 2-[6-[[4-(cyclopropylmethoxy)-3-(trifluoromethyl)phenyl]methoxy]-2,3-dihydro-1h-pyrrolo[1,2-a]indol-3-yl]acetic acid Chemical compound OC(=O)CC1CCN(C2=CC=3)C1=CC2=CC=3OCC(C=C1C(F)(F)F)=CC=C1OCC1CC1 JJIPBGSMNCDBMS-UHFFFAOYSA-N 0.000 claims description 2
- IMXFZVFUJJOUHT-UHFFFAOYSA-N 2-[6-[[4-(fluoromethoxy)-3-(trifluoromethyl)phenyl]methoxy]-2,3-dihydro-1h-pyrrolo[1,2-a]indol-3-yl]acetic acid Chemical compound OC(=O)CC1CCN(C2=CC=3)C1=CC2=CC=3OCC1=CC=C(OCF)C(C(F)(F)F)=C1 IMXFZVFUJJOUHT-UHFFFAOYSA-N 0.000 claims description 2
- DJWFHSYQGCJOFA-UHFFFAOYSA-N 2-[6-[[4-carbamoyl-3-(trifluoromethyl)phenyl]methoxy]-2,3-dihydro-1h-pyrrolo[1,2-a]indol-3-yl]acetic acid Chemical compound C1=C(C(F)(F)F)C(C(=O)N)=CC=C1COC1=CC=C(N2C(C(CC(O)=O)CC2)=C2)C2=C1 DJWFHSYQGCJOFA-UHFFFAOYSA-N 0.000 claims description 2
- WEZSBHGIKFJOED-UHFFFAOYSA-N 2-[6-[[4-chloro-3-(trifluoromethyl)phenyl]methoxy]-2,3-dihydro-1h-pyrrolo[1,2-a]indol-3-yl]acetic acid Chemical compound OC(=O)CC1CCN(C2=CC=3)C1=CC2=CC=3OCC1=CC=C(Cl)C(C(F)(F)F)=C1 WEZSBHGIKFJOED-UHFFFAOYSA-N 0.000 claims description 2
- YYYIRGICSGJFRZ-UHFFFAOYSA-N 2-[6-[[4-cyano-3-(trifluoromethyl)phenyl]methoxy]-2,3-dihydro-1h-pyrrolo[1,2-a]indol-3-yl]acetic acid Chemical compound OC(=O)CC1CCN(C2=CC=3)C1=CC2=CC=3OCC1=CC=C(C#N)C(C(F)(F)F)=C1 YYYIRGICSGJFRZ-UHFFFAOYSA-N 0.000 claims description 2
- WQUODYAJVRWHCT-UHFFFAOYSA-N 2-[6-[[4-cyclopentyl-3-(trifluoromethyl)phenyl]methoxy]-2,3-dihydro-1h-pyrrolo[1,2-a]benzimidazol-3-yl]acetic acid Chemical compound OC(=O)CC1CCN(C2=CC=3)C1=NC2=CC=3OCC(C=C1C(F)(F)F)=CC=C1C1CCCC1 WQUODYAJVRWHCT-UHFFFAOYSA-N 0.000 claims description 2
- PESLCTHINYVCSC-UHFFFAOYSA-N 2-[6-[[4-cyclopentyl-3-(trifluoromethyl)phenyl]methoxy]-2,3-dihydro-1h-pyrrolo[1,2-a]indol-3-yl]acetic acid Chemical compound OC(=O)CC1CCN(C2=CC=3)C1=CC2=CC=3OCC(C=C1C(F)(F)F)=CC=C1C1CCCC1 PESLCTHINYVCSC-UHFFFAOYSA-N 0.000 claims description 2
- JHJIYVPIFOAMEO-UHFFFAOYSA-N 2-[6-[[4-cyclopentyl-3-(trifluoromethyl)phenyl]methoxy]-4-cyclopropyl-2,3-dihydro-1h-pyrrolo[1,2-a]indol-3-yl]acetic acid Chemical compound OC(=O)CC1CCN(C2=CC=C(OCC=3C=C(C(C4CCCC4)=CC=3)C(F)(F)F)C=C22)C1=C2C1CC1 JHJIYVPIFOAMEO-UHFFFAOYSA-N 0.000 claims description 2
- AVDZLJKEGWIFFE-UHFFFAOYSA-N 2-[6-[[4-cyclopentyl-3-(trifluoromethyl)phenyl]methoxy]-4-ethyl-2,3-dihydro-1h-pyrrolo[1,2-a]indol-3-yl]acetic acid Chemical compound C1=C2C(CC)=C3C(CC(O)=O)CCN3C2=CC=C1OCC(C=C1C(F)(F)F)=CC=C1C1CCCC1 AVDZLJKEGWIFFE-UHFFFAOYSA-N 0.000 claims description 2
- YOVAHGXSIQIVHZ-UHFFFAOYSA-N 2-[6-[[4-cyclopentyl-3-(trifluoromethyl)phenyl]methoxy]-4-fluoro-2,3-dihydro-1h-pyrrolo[1,2-a]indol-3-yl]acetic acid Chemical compound OC(=O)CC1CCN(C2=CC=3)C1=C(F)C2=CC=3OCC(C=C1C(F)(F)F)=CC=C1C1CCCC1 YOVAHGXSIQIVHZ-UHFFFAOYSA-N 0.000 claims description 2
- MVTHLCJGJRSEIS-UHFFFAOYSA-N 2-[6-[[4-cyclopentyl-3-(trifluoromethyl)phenyl]methoxy]-4-iodo-2,3-dihydro-1h-pyrrolo[1,2-a]indol-3-yl]acetic acid Chemical compound OC(=O)CC1CCN(C2=CC=3)C1=C(I)C2=CC=3OCC(C=C1C(F)(F)F)=CC=C1C1CCCC1 MVTHLCJGJRSEIS-UHFFFAOYSA-N 0.000 claims description 2
- OKPOPDROEZSIAG-UHFFFAOYSA-N 2-[6-[[4-cyclopentyl-3-(trifluoromethyl)phenyl]methoxy]-4-methyl-2,3-dihydro-1h-pyrrolo[1,2-a]indol-3-yl]acetic acid Chemical compound C1=C2C(C)=C3C(CC(O)=O)CCN3C2=CC=C1OCC(C=C1C(F)(F)F)=CC=C1C1CCCC1 OKPOPDROEZSIAG-UHFFFAOYSA-N 0.000 claims description 2
- LUXNZQWXQVCCSK-UHFFFAOYSA-N 2-[6-[[4-cyclopentyl-3-(trifluoromethyl)phenyl]methoxy]-4-pyridin-2-yl-2,3-dihydro-1h-pyrrolo[1,2-a]indol-3-yl]acetic acid Chemical compound OC(=O)CC1CCN(C2=CC=C(OCC=3C=C(C(C4CCCC4)=CC=3)C(F)(F)F)C=C22)C1=C2C1=CC=CC=N1 LUXNZQWXQVCCSK-UHFFFAOYSA-N 0.000 claims description 2
- ZDPMZXPFSLSBPW-UHFFFAOYSA-N 2-[6-[[4-cyclopentyloxy-3-(trifluoromethyl)phenyl]methoxy]-2,3-dihydro-1h-pyrrolo[1,2-a]indol-3-yl]acetic acid Chemical compound OC(=O)CC1CCN(C2=CC=3)C1=CC2=CC=3OCC(C=C1C(F)(F)F)=CC=C1OC1CCCC1 ZDPMZXPFSLSBPW-UHFFFAOYSA-N 0.000 claims description 2
- DEEQOMQGACQZCH-UHFFFAOYSA-N 2-[6-[[4-methoxy-3-(trifluoromethyl)phenyl]methoxy]-2,3-dihydro-1h-pyrrolo[1,2-a]indol-3-yl]acetic acid Chemical compound C1=C(C(F)(F)F)C(OC)=CC=C1COC1=CC=C(N2C(C(CC(O)=O)CC2)=C2)C2=C1 DEEQOMQGACQZCH-UHFFFAOYSA-N 0.000 claims description 2
- BCGUKCVQRODEEB-UHFFFAOYSA-N 2-[6-[[4-propan-2-yloxy-3-(trifluoromethyl)phenyl]methoxy]-2,3-dihydro-1h-pyrrolo[1,2-a]indol-3-yl]acetic acid Chemical compound C1=C(C(F)(F)F)C(OC(C)C)=CC=C1COC1=CC=C(N2C(C(CC(O)=O)CC2)=C2)C2=C1 BCGUKCVQRODEEB-UHFFFAOYSA-N 0.000 claims description 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 3
- 229940126062 Compound A Drugs 0.000 claims 2
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 230000003612 virological effect Effects 0.000 claims 2
- RWFBHHNEDFDSPE-MRXNPFEDSA-N 2-[(3r)-4-chloro-6-[(3-cyano-4-propan-2-yloxyphenyl)methoxy]-2,3-dihydro-1h-pyrrolo[1,2-a]indol-3-yl]acetic acid Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1COC1=CC=C(N2C([C@@H](CC(O)=O)CC2)=C2Cl)C2=C1 RWFBHHNEDFDSPE-MRXNPFEDSA-N 0.000 claims 1
- XVAKSXTWMLJFSC-GOSISDBHSA-N 2-[(3r)-6-[(3-cyano-4-propan-2-yloxyphenyl)methoxy]-4-methyl-2,3-dihydro-1h-pyrrolo[1,2-a]indol-3-yl]acetic acid Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1COC1=CC=C(N2C([C@@H](CC(O)=O)CC2)=C2C)C2=C1 XVAKSXTWMLJFSC-GOSISDBHSA-N 0.000 claims 1
- PESLCTHINYVCSC-GOSISDBHSA-N 2-[(3r)-6-[[4-cyclopentyl-3-(trifluoromethyl)phenyl]methoxy]-2,3-dihydro-1h-pyrrolo[1,2-a]indol-3-yl]acetic acid Chemical compound C([C@@H]1CC(=O)O)CN(C2=CC=3)C1=CC2=CC=3OCC(C=C1C(F)(F)F)=CC=C1C1CCCC1 PESLCTHINYVCSC-GOSISDBHSA-N 0.000 claims 1
- RWFBHHNEDFDSPE-INIZCTEOSA-N 2-[(3s)-4-chloro-6-[(3-cyano-4-propan-2-yloxyphenyl)methoxy]-2,3-dihydro-1h-pyrrolo[1,2-a]indol-3-yl]acetic acid Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1COC1=CC=C(N2C([C@H](CC(O)=O)CC2)=C2Cl)C2=C1 RWFBHHNEDFDSPE-INIZCTEOSA-N 0.000 claims 1
- XVAKSXTWMLJFSC-SFHVURJKSA-N 2-[(3s)-6-[(3-cyano-4-propan-2-yloxyphenyl)methoxy]-4-methyl-2,3-dihydro-1h-pyrrolo[1,2-a]indol-3-yl]acetic acid Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1COC1=CC=C(N2C([C@H](CC(O)=O)CC2)=C2C)C2=C1 XVAKSXTWMLJFSC-SFHVURJKSA-N 0.000 claims 1
- PESLCTHINYVCSC-SFHVURJKSA-N 2-[(3s)-6-[[4-cyclopentyl-3-(trifluoromethyl)phenyl]methoxy]-2,3-dihydro-1h-pyrrolo[1,2-a]indol-3-yl]acetic acid Chemical compound C([C@H]1CC(=O)O)CN(C2=CC=3)C1=CC2=CC=3OCC(C=C1C(F)(F)F)=CC=C1C1CCCC1 PESLCTHINYVCSC-SFHVURJKSA-N 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 230000036571 hydration Effects 0.000 claims 1
- 238000006703 hydration reaction Methods 0.000 claims 1
- 238000007614 solvation Methods 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 description 16
- 125000003545 alkoxy group Chemical group 0.000 description 10
- 0 C*(CC(CC(O)=O)c1c2*)C[n]1c(cc1)c2c(*)c1OCc1c(*)c(*)c(*)c(*)c1 Chemical compound C*(CC(CC(O)=O)c1c2*)C[n]1c(cc1)c2c(*)c1OCc1c(*)c(*)c(*)c(*)c1 0.000 description 4
- 208000035143 Bacterial infection Diseases 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 208000022362 bacterial infectious disease Diseases 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 239000000556 agonist Substances 0.000 description 2
- 230000036471 bradycardia Effects 0.000 description 2
- 208000006218 bradycardia Diseases 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 125000004438 haloalkoxy group Chemical group 0.000 description 2
- 230000000694 effects Effects 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19031108P | 2008-08-27 | 2008-08-27 | |
| US61/190,311 | 2008-08-27 | ||
| US26951909P | 2009-06-24 | 2009-06-24 | |
| US61/269,519 | 2009-06-24 | ||
| PCT/US2009/004851 WO2010027431A1 (en) | 2008-08-27 | 2009-08-26 | Substituted tricyclic acid derivatives as s1p1 receptor agonists useful in the treatment of autoimmune and inflammatory disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015022889A Division JP2015110641A (ja) | 2008-08-27 | 2015-02-09 | 自己免疫障害および免疫性障害の治療において有用なｓ１ｐ１受容体のアゴニストとしての置換三環式酸誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012501327A JP2012501327A (ja) | 2012-01-19 |
| JP2012501327A5 true JP2012501327A5 (enExample) | 2012-09-20 |
| JP5726737B2 JP5726737B2 (ja) | 2015-06-03 |
Family
ID=41491524
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011524992A Active JP5726737B2 (ja) | 2008-08-27 | 2009-08-26 | 自己免疫障害および免疫性障害の治療において有用なｓ１ｐ１受容体のアゴニストとしての置換三環式酸誘導体 |
| JP2015022889A Abandoned JP2015110641A (ja) | 2008-08-27 | 2015-02-09 | 自己免疫障害および免疫性障害の治療において有用なｓ１ｐ１受容体のアゴニストとしての置換三環式酸誘導体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015022889A Abandoned JP2015110641A (ja) | 2008-08-27 | 2015-02-09 | 自己免疫障害および免疫性障害の治療において有用なｓ１ｐ１受容体のアゴニストとしての置換三環式酸誘導体 |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US8415484B2 (enExample) |
| EP (1) | EP2342205B1 (enExample) |
| JP (2) | JP5726737B2 (enExample) |
| KR (2) | KR101800595B1 (enExample) |
| CN (2) | CN105816453B (enExample) |
| AU (1) | AU2009288738B9 (enExample) |
| BR (1) | BRPI0917923B1 (enExample) |
| CA (1) | CA2733671C (enExample) |
| CY (1) | CY1117830T1 (enExample) |
| EA (1) | EA036955B1 (enExample) |
| ES (1) | ES2583630T3 (enExample) |
| HR (1) | HRP20160890T1 (enExample) |
| HU (1) | HUE031479T2 (enExample) |
| IL (2) | IL211107A0 (enExample) |
| MX (1) | MX2011002199A (enExample) |
| NZ (1) | NZ591001A (enExample) |
| PL (1) | PL2342205T3 (enExample) |
| PT (1) | PT2342205T (enExample) |
| RS (1) | RS54970B1 (enExample) |
| SI (1) | SI2342205T1 (enExample) |
| SM (1) | SMT201600318B (enExample) |
| WO (1) | WO2010027431A1 (enExample) |
| ZA (1) | ZA201101524B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0909625B1 (pt) * | 2008-03-17 | 2021-09-08 | Actelion Pharmaceuticals Ltd | Agonista seletivo do receptor s1p1 para o uso como um medicamento, uso de um agonista seletivo do receptor s1p1 e kit contendo diferentes unidades de medicação de um agonista seletivo do receptor s1p1 |
| US8580841B2 (en) | 2008-07-23 | 2013-11-12 | Arena Pharmaceuticals, Inc. | Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders |
| CN105816453B (zh) | 2008-08-27 | 2021-03-05 | 艾尼纳制药公司 | 用于治疗自身免疫性病症和炎性病症的作为s1p1受体激动剂的经取代的三环酸衍生物 |
| WO2011005295A1 (en) * | 2009-06-24 | 2011-01-13 | Arena Pharmaceuticals, Inc. | Modulators of the sphingosine-1-phosphate (s1p) receptor useful for the treatment of disorders related thereto |
| SG182610A1 (en) | 2010-01-27 | 2012-08-30 | Arena Pharm Inc | Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof |
| CA2789480A1 (en) * | 2010-03-03 | 2011-09-09 | Arena Pharmaceuticals, Inc. | Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof |
| CN104710426B (zh) * | 2014-12-12 | 2017-08-01 | 常州大学 | 苯并吡咯里西啶生物碱及其制备方法和用途 |
| CN104478885B (zh) * | 2014-12-12 | 2017-08-01 | 常州大学 | 9‑氨基‑9a‑烯丙基苯并吡咯里西啶生物碱的制备方法 |
| US11007175B2 (en) | 2015-01-06 | 2021-05-18 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the S1P1 receptor |
| BR112017027656B1 (pt) | 2015-06-22 | 2023-12-05 | Arena Pharmaceuticals, Inc. | Hábito cristalino de placa livre de sal de l-arginina de ácido (r)-2-(7-(4- ciclopentil-3-(trifluorometil)benzilóxi)- 1,2,3,4-tetra-hidrociclo-penta[b]indol-3- il)acético, composição farmacêutica que o compreende, seus usos e método de preparação do mesmo |
| JP2020507610A (ja) | 2017-02-16 | 2020-03-12 | アリーナ ファーマシューティカルズ， インコーポレイテッド | 腸管外症状を伴う炎症性腸疾患の治療のための化合物および方法 |
| CA3053418A1 (en) | 2017-02-16 | 2018-08-23 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of primary biliary cholangitis |
| BR112020024762A2 (pt) | 2018-06-06 | 2021-03-23 | Arena Pharmaceuticals, Inc. | métodos de tratamento de condições relacionadas ao receptor s1p1 |
| CN119751336A (zh) | 2018-09-06 | 2025-04-04 | 艾尼纳制药公司 | 可用于治疗自身免疫性病症和炎性病症的化合物 |
| US12195457B2 (en) | 2018-12-06 | 2025-01-14 | Shanghai Jemincare Pharmaceuticals Co., Ltd; | Aromatic ring derivative as immunoregulation and preparation method and application of aromatic ring derivative |
| EP3906235B1 (en) | 2019-01-04 | 2023-03-15 | Ascentage Pharma (Suzhou) Co., Ltd. | Method for preparing sulfonamides drugs |
| CN113874009A (zh) * | 2019-01-08 | 2021-12-31 | 艾尼纳制药公司 | 治疗与s1p1受体有关的病况的方法 |
| CA3176384A1 (en) * | 2020-04-20 | 2021-10-28 | Xiao-Yan Wen | Method of treating ship1-mediated diseases using pelorol derivatives |
| CN112812052B (zh) * | 2021-02-02 | 2023-12-01 | 成都阿奇生物医药科技有限公司 | 一种治疗溃疡性结肠炎的化合物及其制备方法和用途 |
Family Cites Families (149)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL293572A (enExample) | 1962-06-07 | |||
| DE2226703A1 (de) | 1972-05-25 | 1973-12-13 | Schering Ag | Neue tetrahydrocarbazolderivate und verfahren zu ihrer herstellung |
| US4057559A (en) | 1973-10-01 | 1977-11-08 | American Home Products Corporation | Carbazole acetic acid derivatives |
| US4810699A (en) | 1987-02-20 | 1989-03-07 | American Home Products Corporation | Substituted 1,3,4,9-tetrahydropyrano[3,4,-b]indole-1-acetic acids, pharmaceutical compositions containing them, and methods for treating inflammatory conditions and for analgesic purposes using them |
| US4782076A (en) | 1988-03-01 | 1988-11-01 | American Home Products Corporation | Substituted 2,3,4,9-tetrahydro-1H-carbazole-1-acetic acid derivatives, composition and use |
| PT95692A (pt) | 1989-10-27 | 1991-09-13 | American Home Prod | Processo para a preparacao de derivados de acidos indole-,indeno-,piranoindole- e tetra-hidrocarbazole-alcanoicos, ou quais sao uteis como inibidores de pla2 e da lipoxigenase |
| US5221678A (en) | 1990-07-26 | 1993-06-22 | Merck Frosst Canada, Inc. | (quinolin-2-ylmethoxy)tetrahydrocarbazoles as inhibitors of the biosynthesis of leukotrienes |
| US5998499A (en) | 1994-03-25 | 1999-12-07 | Dentsply G.M.B.H. | Liquid crystalline (meth)acrylate compounds, composition and method |
| US5776967A (en) | 1996-07-26 | 1998-07-07 | American Home Products Corporation | Pyranoindole inhibitors of COX--2 |
| US5830911A (en) | 1996-08-14 | 1998-11-03 | American Home Products Corporation | Pyranoindole and tetrahydrocarbazole inhibitors of COX-2 |
| US6861448B2 (en) | 1998-01-14 | 2005-03-01 | Virtual Drug Development, Inc. | NAD synthetase inhibitors and uses thereof |
| CN101070316A (zh) | 1999-04-28 | 2007-11-14 | 萨诺费－阿文蒂斯德国有限公司 | 作为ppar受体配体的二芳基酸衍生物 |
| US6410583B1 (en) | 2000-07-25 | 2002-06-25 | Merck Frosst Canada & Co. | Cyclopentanoindoles, compositions containing such compounds and methods of treatment |
| AU2002223492A1 (en) | 2000-11-14 | 2002-05-27 | Neurosearch A/S | Use of malaria parasite anion channel blockers for treating malaria |
| AU2002237988B2 (en) | 2001-01-30 | 2008-01-03 | University Of Virginia Patent Foundation | Agonists and antagonists of sphingosine-1-phosphate receptors |
| US7534547B2 (en) | 2001-03-29 | 2009-05-19 | Osaka Gas Company Limited | Optically active compound and photosensitive resin composition |
| EP1391199B1 (en) | 2001-05-10 | 2008-12-10 | Ono Pharmaceutical Co., Ltd. | Carboxylic acid derivatives and drugs containing the same as the active ingredient |
| AU2002332289B2 (en) | 2001-09-27 | 2007-05-10 | Kyorin Pharmaceutical Co., Ltd. | Diaryl sulfide derivative, addition salt thereof, and immunosuppressant |
| AU2003207567B2 (en) | 2002-01-18 | 2008-01-24 | Merck Sharp & Dohme Corp. | Edg receptor agonists |
| AU2003216054B2 (en) | 2002-01-18 | 2007-01-04 | Merck & Co., Inc. | Selective S1P1/Edg1 receptor agonists |
| EP1467729A1 (en) | 2002-01-18 | 2004-10-20 | The Genetics Company Inc. | Beta-secretase inhibitors |
| AU2003218056A1 (en) | 2002-03-01 | 2003-09-16 | Merck & Co., Inc. | Aminoalkylphosphonates and related compounds as edg receptor agonists |
| CA2477423A1 (en) | 2002-03-01 | 2003-09-12 | Merck & Co., Inc. | Aminoalkylphosphonates and related compounds as edg receptor agonists |
| JP2005533058A (ja) | 2002-06-17 | 2005-11-04 | メルク エンド カムパニー インコーポレーテッド | Ｅｄｇ受容体アゴニストとしての１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）アゼチジン−３−カルボキシラートおよび１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）ピロリジン−３−カルボキシラート |
| WO2004007472A1 (ja) | 2002-07-10 | 2004-01-22 | Ono Pharmaceutical Co., Ltd. | Ｃｃｒ４アンタゴニストおよびその医薬用途 |
| EP1546110A4 (en) | 2002-07-30 | 2008-03-26 | Univ Virginia | COMPOUNDS WITH EFFECT ON SIGNAL TRANSMISSION BY SPHINGOSINE-1-PHOSPHATE |
| US7960369B2 (en) | 2002-11-08 | 2011-06-14 | Takeda Pharmaceutical Company Limited | Receptor function regulator |
| EP1581509B1 (en) * | 2002-12-20 | 2011-01-19 | Merck Sharp & Dohme Corp. | 1-(amino)indanes as edg receptor agonists |
| MXPA05008531A (es) | 2003-02-11 | 2005-11-17 | Irm Llc | Compuestos biciclicos novedosos y composiciones. |
| WO2004074297A1 (ja) | 2003-02-18 | 2004-09-02 | Kyorin Pharmaceutical Co., Ltd. | アミノホスホン酸誘導体とその付加塩及びs1p受容体調節剤 |
| EP1628970A2 (en) | 2003-04-30 | 2006-03-01 | The Institutes of Pharmaceutical Discovery, LLC | Heterocycle substituted carboxylic acids as inhibitors of protein tyrosine phosphatase-1b |
| EP1622866B1 (en) | 2003-04-30 | 2012-07-25 | Novartis AG | Aminopropanol derivatives as sphingosine-1-phosphate receptor modulators |
| CN1777575B (zh) | 2003-04-30 | 2010-05-12 | 诺瓦提斯公司 | 作为1-磷酸-鞘氨醇受体调节剂的氨基-丙醇衍生物 |
| WO2004103279A2 (en) | 2003-05-15 | 2004-12-02 | Merck & Co., Inc. | 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as s1p receptor agonists |
| WO2004104205A2 (en) | 2003-05-16 | 2004-12-02 | Merck & Co., Inc. | Enzymatic preparation of chiral indole esters |
| MY150088A (en) | 2003-05-19 | 2013-11-29 | Irm Llc | Immunosuppressant compounds and compositions |
| WO2004113330A1 (en) | 2003-05-19 | 2004-12-29 | Irm Llc | Immunosuppressant compounds and compositions |
| ATE537825T1 (de) | 2003-05-19 | 2012-01-15 | Irm Llc | Immunosuppressive verbindungen und zusammensetzungen |
| AU2004251146A1 (en) | 2003-05-19 | 2005-01-06 | Irm, Llc | Immunosuppressant compounds and compositions |
| GB0313612D0 (en) | 2003-06-12 | 2003-07-16 | Novartis Ag | Organic compounds |
| WO2005012221A1 (ja) | 2003-08-04 | 2005-02-10 | Ono Pharmaceutical Co., Ltd. | ジフェニルエーテル化合物、その製造方法および用途 |
| MXPA06002349A (es) | 2003-08-28 | 2006-05-22 | Novartis Ag | Derivados de aminopropanol. |
| ES2754221T3 (es) | 2003-08-29 | 2020-04-16 | Ono Pharmaceutical Co | Compuesto capaz de unirse al receptor de S1P y uso farmacéutico del mismo |
| US7825109B2 (en) | 2003-08-29 | 2010-11-02 | Ono Pharmaceutical Co., Ltd. | Compound capable of binding S1P receptor and pharmaceutical use thereof |
| JPWO2005023771A1 (ja) | 2003-09-05 | 2006-11-02 | 小野薬品工業株式会社 | ケモカインレセプターアンタゴニストおよびその医薬用途 |
| EP1670463A2 (en) | 2003-10-01 | 2006-06-21 | Merck & Co., Inc. | 3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists |
| US7638637B2 (en) | 2003-11-03 | 2009-12-29 | University Of Virginia Patent Foundation | Orally available sphingosine 1-phosphate receptor agonists and antagonists |
| WO2005044780A1 (ja) | 2003-11-10 | 2005-05-19 | Kyorin Pharmaceutical Co., Ltd. | アミノカルボン酸誘導体とその付加塩及びｓ１ｐ受容体調節剤 |
| CN1894225A (zh) | 2003-12-17 | 2007-01-10 | 默克公司 | 作为鞘氨醇1－磷酸(内皮分化基因)受体激动剂的(3,4－二取代)丙酸酯 |
| US7875745B2 (en) | 2003-12-19 | 2011-01-25 | Ono Pharmaceutical Co., Ltd. | Compounds having lysophosphatidic acid receptor antagonism and uses thereof |
| GB0329498D0 (en) | 2003-12-19 | 2004-01-28 | Novartis Ag | Organic compounds |
| GB0401332D0 (en) | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
| CN1921847B (zh) | 2004-02-24 | 2010-06-16 | 三共株式会社 | 氨基醇化合物 |
| WO2005082841A1 (en) | 2004-02-24 | 2005-09-09 | Irm Llc | Immunosuppressant compounds and compositions |
| TW200538433A (en) | 2004-02-24 | 2005-12-01 | Irm Llc | Immunosuppressant compounds and compositiions |
| CN1934094A (zh) | 2004-03-05 | 2007-03-21 | 万有制药株式会社 | 二芳基取代杂环5元环衍生物 |
| GB0405289D0 (en) | 2004-03-09 | 2004-04-21 | Novartis Ag | Organic compounds |
| TWI344954B (en) | 2004-04-02 | 2011-07-11 | Merck Sharp & Dohme | Asymmetric hydrogenation process |
| WO2005123677A1 (en) | 2004-06-16 | 2005-12-29 | Actelion Pharmaceuticals Ltd | 4-carbonyl substituted 1,1,2-trimethyl-1a,4,5,5a-tetrahydro-1h-4-aza-cyclopropa'a!pentalene derivatives as agonists for the g-protein-coupled receptor s1p1/edg1 and immunosuppressive agents |
| WO2006001463A1 (ja) | 2004-06-23 | 2006-01-05 | Ono Pharmaceutical Co., Ltd. | Ｓ１ｐ受容体結合能を有する化合物およびその用途 |
| AU2005264431B2 (en) | 2004-07-16 | 2010-08-19 | Kyorin Pharmaceutical Co., Ltd. | Method of effectively using medicine and method concerning prevention of side effect |
| JP2007284350A (ja) | 2004-07-27 | 2007-11-01 | Takeda Chem Ind Ltd | 糖尿病治療剤 |
| TW200611687A (en) | 2004-07-29 | 2006-04-16 | Sankyo Co | Pharmaceutical compositions used for immunosuppressant |
| WO2006010379A1 (en) | 2004-07-29 | 2006-02-02 | Actelion Pharmaceuticals Ltd. | Novel thiophene derivatives as immunosuppressive agents |
| JP4993407B2 (ja) | 2004-08-04 | 2012-08-08 | 大正製薬株式会社 | トリアゾール誘導体 |
| US20060223866A1 (en) | 2004-08-13 | 2006-10-05 | Praecis Pharmaceuticals, Inc. | Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity |
| BRPI0514316A (pt) | 2004-08-13 | 2008-06-10 | Praecis Pharm Inc | métodos e composições para modulação de atividade de receptor de esfingosina-1-fosfato (s1p) |
| BRPI0515596A (pt) | 2004-09-23 | 2008-07-29 | Wyeth Corp | composição farmacêutica usada para o tratamento e/ou prevenção de hcv, e, métodos de inibir rna polimerase ns5b de hepatite c de tratar ou prevenir infecção por hepatite c em um mamìfero |
| CA2583947A1 (en) | 2004-10-12 | 2006-04-20 | Forbes Medi-Tech (Research) Inc. | Compounds and methods of treating insulin resistance and cardiomyopathy |
| CN101043887A (zh) | 2004-10-22 | 2007-09-26 | 默克公司 | 用作s1p受体激动剂的2－(芳基)氮杂环甲基羧酸酯、磺酸酯、膦酸酯、次膦酸酯和杂环化合物 |
| SI1650186T1 (sl) | 2004-10-22 | 2008-12-31 | Bioprojet Soc Civ | Novi derivati dikarboksilne kisline |
| WO2006055708A2 (en) | 2004-11-18 | 2006-05-26 | The Institutes For Pharmaceutical Discovery, Llc | Heterocycle substituted carboxylic acids for the treatment of diabetes |
| US20080051418A1 (en) | 2004-11-26 | 2008-02-28 | Tsuyoshi Maekawa | Arylalkanoic Acid Derivative |
| US7888527B2 (en) | 2004-12-06 | 2011-02-15 | University Of Virginia Patent Foundation | Aryl amide sphingosine 1-phosphate analogs |
| EP2371811B1 (en) | 2004-12-13 | 2014-10-08 | Ono Pharmaceutical Co., Ltd. | Azetidinecarboxylic acid derivative and medicinal use thereof |
| WO2006079406A1 (en) | 2005-01-25 | 2006-08-03 | Merck Patent Gmbh | Mesogenic compounds, liquid crystal medium and liquid crystal display |
| JP2008530135A (ja) | 2005-02-14 | 2008-08-07 | ユニバーシティ オブ バージニア パテント ファンデーション | アミノ基およびフェニル基で置換されたシクロアルカンならびに５員の複素環を含むスフィンゴシン＝１−リン酸アゴニスト |
| DE602006003642D1 (en) | 2005-03-23 | 2008-12-24 | Actelion Pharmaceuticals Ltd | Neue thiophen-derivate als sphingosin-1-phosphat-1-rezeptorantagonisten |
| HRP20110613T1 (hr) | 2005-03-23 | 2011-09-30 | Actelion Pharmaceuticals Ltd. | Hidrogenizirani derivati benzo[c] tiofena kao imunomodulatori |
| CN101180050B (zh) | 2005-03-23 | 2011-07-27 | 埃科特莱茵药品有限公司 | 作为鞘氨醇-1-磷酸盐-1受体激动剂的新颖噻吩衍生物 |
| BRPI0612028A2 (pt) | 2005-06-08 | 2010-10-13 | Novartis Ag | oxadiazóis ou isodiazóis policìclicos e uso dos mesmos como ligantes de receptor s1p |
| TWI418350B (zh) | 2005-06-24 | 2013-12-11 | Sankyo Co | 含有ｐｐａｒ調節劑之醫藥組成物的用途 |
| US7951794B2 (en) | 2005-06-24 | 2011-05-31 | Actelion Pharmaceuticals Ltd. | Thiophene derivatives |
| US20070060573A1 (en) | 2005-08-10 | 2007-03-15 | Lars Wortmann | Acyltryptophanols |
| RU2008110949A (ru) | 2005-08-23 | 2009-09-27 | Айрм Ллк (Bm) | Соединения и композиции-иммуносупрессанты |
| WO2007037196A1 (ja) | 2005-09-29 | 2007-04-05 | Yamamoto Chemicals, Inc. | インドリン系化合物及びその製造方法 |
| CA2630714C (en) | 2005-11-23 | 2014-01-14 | Epix Delaware, Inc. | S1p receptor modulating compounds and use thereof |
| AR057894A1 (es) | 2005-11-23 | 2007-12-26 | Actelion Pharmaceuticals Ltd | Derivados de tiofeno |
| TWI404706B (zh) | 2006-01-11 | 2013-08-11 | Actelion Pharmaceuticals Ltd | 新穎噻吩衍生物 |
| TW200736234A (en) | 2006-01-17 | 2007-10-01 | Astrazeneca Ab | Chemical compounds |
| KR20080092385A (ko) | 2006-01-24 | 2008-10-15 | 액테리온 파마슈티칼 리미티드 | 신규한 피리딘 유도체 |
| GB0601744D0 (en) | 2006-01-27 | 2006-03-08 | Novartis Ag | Organic compounds |
| TWI389683B (zh) | 2006-02-06 | 2013-03-21 | Kyorin Seiyaku Kk | A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient |
| TW200806611A (en) | 2006-02-09 | 2008-02-01 | Daiichi Seiyaku Co | Novel amidopropionic acid derivatives and medicine containing the same |
| JP2009526073A (ja) | 2006-02-09 | 2009-07-16 | ユニバーシティ オブ バージニア パテント ファンデーション | 二環式スフィンゴシン−１−リン酸受容体アナログ |
| US20070191371A1 (en) | 2006-02-14 | 2007-08-16 | Kalypsys, Inc. | Heterocyclic modulators of ppar |
| EP1984334B1 (en) | 2006-02-15 | 2014-04-09 | Allergan, Inc. | Indole-3-carboxylic acid amide, ester, thioamide and thiol ester compounds bearing aryl or heteroaryl groups having sphingosine-1-phosphate (s1p) receptor antagonist biological activity |
| CN101460458A (zh) | 2006-02-15 | 2009-06-17 | 阿勒根公司 | 具有1－磷酸－鞘氨醇(s1p)受体拮抗剂生物活性的带芳基或者杂芳基基团的吲哚－3－羧酸的酰胺、酯、硫代酰胺和硫羟酸酯化合物 |
| JP2009527501A (ja) | 2006-02-21 | 2009-07-30 | ユニバーシティ オブ バージニア パテント ファンデーション | Ｓ１ｐ受容体アゴニストとしてのフェニル−シクロアルキル誘導体およびフェニル−複素環誘導体 |
| US7649098B2 (en) | 2006-02-24 | 2010-01-19 | Lexicon Pharmaceuticals, Inc. | Imidazole-based compounds, compositions comprising them and methods of their use |
| WO2007106469A2 (en) | 2006-03-14 | 2007-09-20 | Amgen Inc. | Bicyclic carboxylic acid derivatives useful for treating metabolic disorders |
| CA2646469A1 (en) | 2006-03-21 | 2007-09-27 | Epix Delaware, Inc. | S1p receptor modulating compounds |
| JP2007262009A (ja) | 2006-03-29 | 2007-10-11 | Dai Ichi Seiyaku Co Ltd | ヘテロアリール低級カルボン酸誘導体 |
| AU2007236707C1 (en) | 2006-04-03 | 2012-05-24 | Astellas Pharma Inc. | Hetero compound |
| GB0607389D0 (en) | 2006-04-12 | 2006-05-24 | Novartis Ag | Organic compounds |
| WO2007129473A1 (ja) | 2006-05-09 | 2007-11-15 | Daiichi Sankyo Company, Limited | 二環性アリール誘導体 |
| EP2258700A1 (en) | 2006-05-09 | 2010-12-08 | Pfizer Products Inc. | Cycloalkylamino acid derivatives and pharmaceutical compositions thereof |
| JPWO2007129745A1 (ja) | 2006-05-09 | 2009-09-17 | 第一三共株式会社 | ヘテロアリールアミド低級カルボン酸誘導体 |
| EP2046766A1 (en) | 2006-08-01 | 2009-04-15 | Praecis Pharmaceuticals Incorporated | Agonists of the sphingosine- 1- phosphate receptor (slp) |
| TW200823182A (en) | 2006-08-01 | 2008-06-01 | Praecis Pharm Inc | Chemical compounds |
| EP2099768A2 (en) | 2006-08-04 | 2009-09-16 | Praecis Pharmaceuticals Incorporated | Agonists of the sphingosine-1-phosphate receptor |
| NZ574011A (en) | 2006-08-08 | 2011-10-28 | Kyorin Seiyaku Kk | Aminophosphoric acid ester derivative and s1p receptor modulator containing the same as active ingredient |
| WO2008024196A1 (en) | 2006-08-24 | 2008-02-28 | Praecis Pharmaceuticals Incorporated | Chemical compounds |
| JP2009269819A (ja) | 2006-08-25 | 2009-11-19 | Asahi Kasei Pharma Kk | アミン化合物 |
| BRPI0716815A2 (pt) | 2006-09-07 | 2013-11-05 | Allergan Inc | Co posto heteroatomáticos tendo atividade biológia agonista e/ou antagonista de receptor de esfinfosina-1-fosfato (s1p) |
| TWI408139B (zh) | 2006-09-07 | 2013-09-11 | Actelion Pharmaceuticals Ltd | 新穎噻吩衍生物 |
| MY149853A (en) | 2006-09-07 | 2013-10-31 | Actelion Pharmaceuticals Ltd | Pyridin-4-yl derivatives as immunomodulating agents |
| AU2007293653B2 (en) | 2006-09-08 | 2011-02-17 | Novartis Ag | N-biaryl (hetero) arylsulphonamide derivatives useful in the treatment of diseases mediated by lymphocytes interactions |
| JP5250556B2 (ja) | 2006-09-21 | 2013-07-31 | アクテリオン ファーマシューティカルズ リミテッド | フェニル誘導体及びそれらの免疫調節薬としての使用 |
| AU2007334436A1 (en) | 2006-12-15 | 2008-06-26 | Abbott Laboratories | Novel oxadiazole compounds |
| JO2701B1 (en) * | 2006-12-21 | 2013-03-03 | جلاكسو جروب ليميتد | Vehicles |
| AU2007338700A1 (en) | 2006-12-21 | 2008-07-03 | Abbott Laboratories | Sphingosine-1 -phosphate receptor agonist and antagonist compounds |
| GB0625648D0 (en) | 2006-12-21 | 2007-01-31 | Glaxo Group Ltd | Compounds |
| AU2008206495A1 (en) | 2007-01-11 | 2008-07-24 | Allergan, Inc. | 6-substituted indole-3-carboxylic acid amide compounds having Sphingosine-1-Phosphate (S1P) receptor antagonist biological activity |
| WO2008091967A1 (en) | 2007-01-26 | 2008-07-31 | Smithkline Beecham Corporation | Chemical compounds |
| WO2008097819A2 (en) | 2007-02-05 | 2008-08-14 | Smithkline Beecham Corporation | Chemical compounds |
| DK2125797T3 (da) | 2007-03-16 | 2014-02-10 | Actelion Pharmaceuticals Ltd | Aminopyridinderivater som s1p1/edg1-receptoragonister |
| CA2679980A1 (en) | 2007-03-21 | 2007-09-27 | Epix Pharmaceuticals, Inc. | S1p receptor modulating compounds and use thereof |
| US8324254B2 (en) | 2007-04-19 | 2012-12-04 | Glaxo Group Limited | Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate (S1P) agonists |
| EP2014653A1 (en) | 2007-06-15 | 2009-01-14 | Bioprojet | Novel dicarboxylic acid derivatives as S1P1 receptor agonists |
| WO2009011850A2 (en) | 2007-07-16 | 2009-01-22 | Abbott Laboratories | Novel therapeutic compounds |
| WO2009019506A1 (en) | 2007-08-03 | 2009-02-12 | Astrazeneca Ab | Heterocyclyc sulfonamides having edg-1 antagonistic activity |
| BRPI0814975A2 (pt) | 2007-08-08 | 2015-02-03 | Merck Serono Sa | Derivados de 6-amino-pirimidina-4-carboxamida e compostos relacionados que se ligam ao receptor de 1-fosfato de esfingosina (s1p) para o tratamento de esclerose múltipla |
| TW200930368A (en) | 2007-11-15 | 2009-07-16 | Astrazeneca Ab | Bis-(sulfonylamino) derivatives in therapy |
| JP2011506600A (ja) | 2007-12-18 | 2011-03-03 | アリーナ ファーマシューティカルズ， インコーポレイテッド | 自己免疫性障害および炎症性障害の治療において有用なテトラヒドロシクロペンタ［ｂ］インドール−３−イルカルボン酸誘導体 |
| US20100292233A1 (en) | 2008-01-25 | 2010-11-18 | Arena Pharmaceuticals, Inc. | Dihydro-1h-pyrrolo[1,2-a]indol-1-yl carboxylic acid derivatives which act as s1p1 agonists |
| AR070398A1 (es) | 2008-02-22 | 2010-03-31 | Gruenenthal Chemie | Derivados sustituidos de indol |
| PL2291080T3 (pl) | 2008-05-14 | 2015-12-31 | Scripps Research Inst | Nowe modulatory receptorów sfingozyno-1-fosforanu |
| WO2009151626A1 (en) | 2008-06-13 | 2009-12-17 | Arena Pharmaceuticals, Inc. | Substituted (1, 2, 4-0xadiaz0l-3-yl) indolin-1-yl carboxylic acid derivatives useful as s1p1 agonists |
| WO2009151621A1 (en) | 2008-06-13 | 2009-12-17 | Arena Pharmaceuticals, Inc. | Substituted (1, 2, 4-0xadiaz0l-3-yl) indolin-1-yl carboxylic acid derivatives useful as s1p1 agonists |
| US8580841B2 (en) | 2008-07-23 | 2013-11-12 | Arena Pharmaceuticals, Inc. | Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders |
| CN105816453B (zh) * | 2008-08-27 | 2021-03-05 | 艾尼纳制药公司 | 用于治疗自身免疫性病症和炎性病症的作为s1p1受体激动剂的经取代的三环酸衍生物 |
| PE20120578A1 (es) | 2009-02-10 | 2012-06-17 | Abbott Lab | Agonistas y antagonistas del receptor de s1p5, y metodos de uso de los mismos |
| WO2011005290A1 (en) | 2009-06-23 | 2011-01-13 | Arena Pharmaceuticals, Inc. | Disubstituted oxadiazole derivatives useful in the treatment of autoimmune and inflammatory disorders |
| WO2011005295A1 (en) | 2009-06-24 | 2011-01-13 | Arena Pharmaceuticals, Inc. | Modulators of the sphingosine-1-phosphate (s1p) receptor useful for the treatment of disorders related thereto |
| ES2759949T3 (es) | 2009-10-29 | 2020-05-12 | Bristol Myers Squibb Co | Compuestos heterocíclicos tricíclicos |
| SG182610A1 (en) | 2010-01-27 | 2012-08-30 | Arena Pharm Inc | Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof |
| CA2789480A1 (en) | 2010-03-03 | 2011-09-09 | Arena Pharmaceuticals, Inc. | Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof |
| JP2013533286A (ja) | 2010-07-30 | 2013-08-22 | セントルイス ユニバーシティ | 疼痛を治療する方法 |
-
2009
- 2009-08-26 CN CN201610178764.9A patent/CN105816453B/zh active Active
- 2009-08-26 PT PT97892103T patent/PT2342205T/pt unknown
- 2009-08-26 EA EA201170374A patent/EA036955B1/ru not_active IP Right Cessation
- 2009-08-26 BR BRPI0917923-2A patent/BRPI0917923B1/pt active IP Right Grant
- 2009-08-26 HR HRP20160890TT patent/HRP20160890T1/hr unknown
- 2009-08-26 SI SI200931475A patent/SI2342205T1/sl unknown
- 2009-08-26 ES ES09789210.3T patent/ES2583630T3/es active Active
- 2009-08-26 CA CA2733671A patent/CA2733671C/en active Active
- 2009-08-26 NZ NZ591001A patent/NZ591001A/xx unknown
- 2009-08-26 HU HUE09789210A patent/HUE031479T2/en unknown
- 2009-08-26 CN CN200980142790.4A patent/CN102197038B/zh active Active
- 2009-08-26 WO PCT/US2009/004851 patent/WO2010027431A1/en not_active Ceased
- 2009-08-26 RS RS20160577A patent/RS54970B1/sr unknown
- 2009-08-26 PL PL09789210.3T patent/PL2342205T3/pl unknown
- 2009-08-26 MX MX2011002199A patent/MX2011002199A/es active IP Right Grant
- 2009-08-26 EP EP09789210.3A patent/EP2342205B1/en active Active
- 2009-08-26 KR KR1020177014649A patent/KR101800595B1/ko active Active
- 2009-08-26 US US13/060,477 patent/US8415484B2/en active Active
- 2009-08-26 AU AU2009288738A patent/AU2009288738B9/en active Active
- 2009-08-26 KR KR1020117006863A patent/KR20110058849A/ko not_active Ceased
- 2009-08-26 JP JP2011524992A patent/JP5726737B2/ja active Active
-
2011
- 2011-02-07 IL IL211107A patent/IL211107A0/en unknown
- 2011-02-25 ZA ZA2011/01524A patent/ZA201101524B/en unknown
-
2013
- 2013-03-06 US US13/787,233 patent/US9108969B2/en active Active
-
2014
- 2014-07-30 IL IL233869A patent/IL233869A/en active IP Right Grant
-
2015
- 2015-02-09 JP JP2015022889A patent/JP2015110641A/ja not_active Abandoned
- 2015-08-04 US US14/817,954 patent/US20150336966A1/en not_active Abandoned
-
2016
- 2016-07-20 CY CY20161100713T patent/CY1117830T1/el unknown
- 2016-09-14 SM SM201600318T patent/SMT201600318B/it unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012501327A5 (enExample) | ||
| JP6236173B2 (ja) | 脊髄性筋萎縮症を処置するための化合物 | |
| JP6063870B2 (ja) | ＲＯＲγ活性の阻害用のＮ−スルホニル化テトラヒドロキノリンおよび関連二環化合物および病気の治療 | |
| JP2011529049A5 (enExample) | ||
| JP2020519589A5 (enExample) | ||
| JP6259463B2 (ja) | ＩＬ−１２、ＩＬ−２３および／またはＩＦＮα応答のモジュレーターとして有用であるアルキルアミド置換ピリジル化合物 | |
| HRP20160890T1 (hr) | Derivati supstituirane tricikličke kiseline kao agonisti s1p1-receptora korisni u liječenju autoimunih i upalnih poremećaja | |
| EP2114903B1 (en) | Bicyclic pyrimidinones and uses thereof | |
| KR20210086674A (ko) | Il-12, il-23 및/또는 ifn-알파의 조정과 관련된 상태의 치료를 위한 아미드-치환된 헤테로시클릭 화합물 | |
| TW201107316A (en) | Oxazine derivatives and their use in the treatment of neurological disorders | |
| JP2013519724A5 (enExample) | ||
| CN103096718A (zh) | 可溶性鸟苷酸环化酶活化剂 | |
| US9512119B2 (en) | Difluoromethylene compound | |
| HRP970432A2 (en) | Substituted pyrido- or pyrimido-containing 6,6- or 6,7-bicyclic derivatives | |
| WO2011100607A1 (en) | Pyrazolopyridine, pyrazolopyrazine, pyrazolopyrimidine, pyrazolothiophene and pyrazolothiazole compounds as mglur4 allosteric potentiators, compounds, and methods of treating neurological dysfunction | |
| WO2012080230A1 (en) | 6 substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders | |
| TW201904942A (zh) | 經取代５-氰基吲哚化合物及其用途 | |
| EP2247601B1 (en) | Thiazopyrimidinones and uses thereof | |
| JP2016520118A5 (enExample) | ||
| TWI291467B (en) | CCR1 antagonists and methods of use therefor | |
| JP2021091716A (ja) | ３−（（ヘテロ−）アリール）−８−アミノ−２−オキソ−１，３−ジアザ−スピロ−［４．５］−デカン誘導体 | |
| JP2017536409A5 (enExample) | ||
| US20200069691A1 (en) | Heterocyclic compounds as hiv protease inhibitors | |
| JP2013507426A5 (enExample) | ||
| WO2017012647A1 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders |